Supplement 4: Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group

| First author (Year) | clearly stated | e 2. eligibility criteria clearly described | pants re- presenta- tive of po- pulation | 4. all eligi- ble partici- pants en- rolled | 5. sample size suffi- ciently large | tion clearly described | clearly de- fined | sors blinded to partici- pants' in- terventions | | 10. statistical examination of pre-post changes | | 12. multi- level struc- ture |
|---|-------------------|--|---|--|--|---------------------------|----------------------|---|--------------|---|-----|------------------------------------|
| | F | Patients with | idiopathic | normal pre | ssure hydro | ocephalus (| PwiNPH) – s | surgical an | d invasive p | procedures | | |
| Ferrari (2020) | yes | yes | yes | yes | NR | yes | no | NR | NR | no | yes | NA |
| Ferrari (2022) | yes | yes | yes | yes | yes | yes | no | NR | yes | yes* | yes | NA |
| Yamada (2019) | yes | yes | yes | yes | NR | yes | yes | NR | yes | no | yes | NA |
| Ishikawa (2019) | yes | no | yes | no | NR | yes | yes | NR | yes | yes | yes | NA |
| | | | Patients v | with Parkins | on's diseas | se (PwPD) - | pharmacolo | ogical inter | vention | | | |
| Dibilio (2017) | yes | yes | yes | NR | NR | yes | no | NR | yes | yes | yes | NA |
| Miller Koop (2018) | yes | yes | yes | NR | NR | yes | no | yes | NR | yes | yes | NA |
| | | | | Orth | opedic con | ditions – ele | ctive surge | ry | | | | |
| Bloomfield (2019) | yes | yes | yes | NR | NR | yes | no | NR | no | yes | yes | NA |
| Perelgut (2020) | yes | yes | yes | NR | yes | yes | no | NR | yes | yes | yes | NA |
| | | E | Exercise an | | | ntions in di | | | pulations | | | |
| | | | | Patie | nts with Pa | rkinson's di | sease (PwP | 'D) | | | | |
| Flood (2020) | yes | yes | yes | NR | NR | yes | no | NR | NR | yes | yes | NA |
| Mollinedo- Cardalda (2018) | yes | yes | yes | yes | yes | yes | no | no | yes | yes | NR | NA |
| Picardi (2020) | yes | yes | yes | NR | NR | no | yes | NR | NR | yes | yes | NA |
| Participants recruited in outpatient settings | | | | | | | | | | | | |
| Smith (2021) | yes | yes | yes | NR | yes | yes | no | NR | no | yes* | NR | NA |

| First author (Year) | 1. objective clearly stated | 2. eligibility criteria clearly described | 3. participants representative of population | 4. all eligi- ble partici- pants en- rolled | 5. sample size suffi- ciently large | 6. intervention clearly described | 7. outcome measures clearly de- fined | 8. assessors blinded to participants' interventions | 9. loss to follow up 20% or less | 10. statistical examination of pre-post changes | | 12. multi- level struc- ture |
|--|-----------------------------|--|--|--|--|-----------------------------------|--|---|---|---|-----|------------------------------------|
| Celletti (2020) | yes | yes | yes | NR | NR | yes | no | NR | yes | yes | NR | NA |
| Doheny (2013) | yes | no | yes | NR | NR | yes | no | NR | yes | yes | yes | NA |
| Williams (2021) | yes | yes | yes | yes | no | yes | no | yes | no | yes | no | NA |
| Participants recruited in inpatient and institutionalized settings | | | | | | | | | | | | |
| Caronni (2019) | yes | yes | yes | NR | NR | yes | yes | NR | yes | yes | yes | NA |
| Cancela Carral (2017) | yes | yes | yes | NR | NR | yes | no | no | no | yes | NR | NA |
| Cancela Carral (2019) | yes | yes | yes | NR | no | yes | no | NR | yes | yes | NR | NA |
| Assistive devices | | | | | | | | | | | | |
| Toosizadeh (2020) | yes | yes | yes | NR | NR | yes | no | NR | NR | no | yes | NA |
| Yalla (2014) | yes | yes | yes | NR | yes | yes | no | NR | NR | yes* | NR | NA |

Notes: yes* = if intention-to-treat analysis was reported

Items and specific criteria for quality rating

| Items | yes | no | | | | |
|---|---|--|--|--|--|--|
| Was the study question or objective clearly stated? | if study question/objective clearly stated | if study question/objective not clearly stated | | | | |
| 2. Were eligibility/selection criteria for the study population prespecified and clearly described? | if criteria prespecified and clearly described | if criteria not prespecified/not sufficiently described | | | | |
| 3. Were the participants in the study representative of those who would be eligible for the test/service/intervention in the general or clinical population of interest? | yes for all studies, because inclusion criteria were age > 60 years; congenital, non-aged-related, or orphan diseases were excluded | | | | | |
| 4. Were all eligible participants that met the prespecified entry criteria enrolled? | if flowchart or description of enrollment provided | if further in/exclusion criteria were added after recrtuiting or enrollment with no reason | | | | |
| 5. Was the sample size sufficiently large to provide confidence in the findings? | if sample size calculation reported and sufficient sample size achieved | if sufficient sample size was not achieved | | | | |
| 6. Was the test/service/intervention clearly described and delivered consistently across the study population? | if intervention is clearly described | if information on duration, frequency, type of intervention missing | | | | |
| 7. Were the outcome measures prespecified, clearly defined, valid, reliable, and assessed consistently across all study participants? | if outcome measures prespecified ad cleary described | if information on iTUG distance, repetitions, sensors, body placement, instruction missing (see table 2) | | | | |
| 8. Were the people assessing the outcomes blinded to the participants' exposures/interventions? | if assessors were blinded | if assessors were not blinded | | | | |
| 9. Was the loss to follow-up after baseline 20% or less? Were those lost to follow-up | yes: if loss to follow-up ≤ 20%; | if loss to follow-up >20% | | | | |
| accounted for in the analysis? | yes*: if intention-to-treat analysis was reported | | | | | |
| 10. Did the statistical methods examine changes in outcome measures from before | yes: if p values reported for pre-post changes; | if descriptive statistics only if no p value reported | | | | |
| to after the intervention? Were statistical tests done that provided p values for the pre-to-post changes? | yes*: if confidence intervals are also available for all reported data | | | | | |
| 11. Were outcome measures of interest taken multiple times before the intervention and multiple times after the intervention (i.e., did they use an interrupted time-series design)? | if > 1 iTUG repetition per measurement timepoint | if only 1 iTUG repetition | | | | |
| 12. If the intervention was conducted at a group level (e.g., a whole hospital, a community, etc.) did the statistical analysis take into account the use of individual-level data to determine effects at the group level? | NA for all studies, none of the included studies was conducted at a group level | | | | | |